Exploration of the Mechanism of Mume Fructus-Bombyx Batryticatus in Treating Children's Adenoid Hypertrophy Based on Network Pharmacology and Molecular Docking Technology
Abstract: Objective: To explore the active components and mechanism of Mume Fructus- Bombyx Batryticatus in the treatment of children's adenoid hypertrophy (AH) by network pharmacology and molecular docking technology. Methods: Target information of Mume Fructus and Bombyx Batryticatus was obtained through the Traditional Chinese Medicine System Pharmacological Database and Analysis Platform (TCMSP) database and Uniprot database. AH-related targets were obtained using GeneCards and OMIM databases, and the intersecting targets were input into the STRING database to obtain protein- protein interaction (PPI). PPI network was constructed using Cytoscape 3.7.0 to screen core targets. And the Metascape database was used to conduct GO function and KEGG pathway enrichment analysis on the target of Mume Fructus- Bombyx Batryticatus for AH treatment. Results : Quercetin , ecdysone , kaempferol,etc. were screened as the main active components of Mume Fructus- Bombyx Batryticatus. There were 539 action targets,165 AH-related targets,including core targets such as cell tumor antigen p53 (TP53), transcription signal sensor and activator 3 (STAT3). GO enrichment analysis yielded 2 188 biological processes, 3 478 molecular functions, and 92 cell components, KEGG analysis involves 200 signaling pathways,including cancer pathway,Th17 cell differentiation pathway,C- type lectin receptor signaling pathway and other key signaling pathways. The results of molecular docking showed that the three main active components of Mume Fructus- Bombyx Batryticatus had good affinity with the core targets MAPK3, STAT3, TP53 and SRC, especially quercetin and STAT3, ecdysone and TP53 had the best binding activity. Conclusion:Mume Fructus-Bombyx Batryticatus may treat AH through anti-inflammatory, immune,antioxidant,vascular inhibition,and induction of cell apoptosis pathways.